US Food and Drug Administration Shifts to AI-Enhanced Regulatory Review With Elsa 4.0 and HALO
-
By
-
Tejas S Athni
-
May 29, 2026
-
Clinical Scorecard: FDA Embraces AI-Driven Regulatory Processes with the Introduction of Elsa 4.0 and HALO Platform
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Integration of AI for data querying and synthesis |
| Target Population | FDA regulatory staff and patients awaiting therapies |
| Care Setting | Federal health regulatory environment |
Key Highlights
- Elsa 4.0 enhances AI integration in FDA workflows.
- HALO platform consolidates over 40 FDA systems for streamlined data access.
- AI capabilities include automated chart generation and optical character recognition.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- AI error propagation across the review pipeline.
- Workforce instability due to abrupt employee terminations.
Patient & Prescribing Data
Patients requiring access to novel therapies and devices
Faster access to therapies through improved regulatory processes.
Clinical Best Practices
- Ensure robust human verification of AI outputs.
- Maintain data security and confidentiality in AI training.
Related Resources & Content
